Video

Dr. Abou-Alfa on Doxorubicin Plus Sorafenib in Liver Cancer

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma (HCC).

The phase III randomized trial showed benefit in overall survival (OS), progression-free survival (PFS), and time to progression (TTP). Median OS was 13.7 months in the doxorubicin-sorafenib arm (95% CI, 8.9--not reached) and 6.5 months (95% CI, 4.5-9.9; P = .006) in the doxorubicin-placebo arm. PFS also showed benefit: 6.0 months (95% CI, 4.6-8.6) versus 2.7 months (95% CI, 1.4-2.8; P = .006). Median TTP was 6.4 months (95% CI, 4.8-9.2) compared to 2.8 months (95% CI, 1.6-5) (P = .02).

Abou-Alfa notes that research must be completed to determine whether the benefit is related to sorafenib or if true synergistic activity is taking place. The ASK1 molecule works well with a RAF kinase inhibitor such as sorafenib and is crucial for an anthracycline such as doxorubicin to cause apoptosis.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School